Infectious Disease Weekly - Schering Says Hepatitis Drug Matches Roche Medicine

[Guest guest]

If you are having problems viewing this message, please use this link

View All Infectious Disease News | Manage Subscriptions |

TherapeuticsDaily.com

Wednesday January 16, 2008

sponsored by:

Schering Says Hepatitis Drug Matches Roche MedicineFrom Reuters Health - Jan 14,

2008NEW YORK (Reuters) - Schering-Plough Corp said on Monday that its Pegintron

treatment for hepatitis C was just as effective as Roche Holding AG's rival

Pegasys medicine in a large clinical trial, and fewer patients taking Pegintron

relapsed after treatment. Read Full Article Article Summary Related Article:

Roche responds to announcement of 'IDEAL' hepatitis C trial results

Featured Solutions Provider

The Corporate Access Program (CAP) is a customized service designed to provide

company-wide access to pharmaceutical market intelligence through our highly

respected interactive products. CAP membership offers a cost and time-effective

approach to distributing relevant industry news and information to your

colleagues.Click here for more information. Three Rivers Pharmaceuticals

Acquires Hepatitis C Drug Infergen From Valeant PharmaceuticalsFrom PR Newswire

Europe (inc. UK Disclose) - Jan 14, 2008CRANBERRY TOWNSHIP, Pa., Jan. 14

/PRNewswire/ -- Three Rivers Pharmaceuticals, LLC finalized acquisition of the

hepatitis C drug Infergen from Valeant Pharmaceuticals International . Valeant

is receiving $91 million from Three Rivers for the procurement. Read Full

Article Article Summary

Pharmasset Jumps on Promising Hepatitis C Trial DataFrom Reuters Health - Jan

08, 2008BANAGALORE (Reuters) - Shares of Pharmasset Inc rose 38 percent on

Tuesday, a day after the pharmaceutical company said preliminary results from an

early stage trial of its hepatitis C treatment showed promise. Tuesday's jump

marks the second straight day the stock has risen significantly. On Monday, it

had closed up more than 44 percent. Pharmasset said on Monday its treatment,

R7128, showed strong short-term antiviral activity and was generally safe and

well-tolerated in 50 patients chronically infected with hepatitis C virus. Read

Full Article Article Summary

Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP

Healthcare ConferenceFrom Hepatitis Weekly - Jan 14, 2008Idenix Pharmaceuticals,

Inc. , a biopharmaceutical company engaged in the discovery and development of

drugs for the treatment of human viral and other infectious diseases, announced

an update on the company's HCV pipeline, including promising second-generation

polymerase and protease inhibitor compounds for the treatment of hepatitis C.

Read Full Article Article Summary

LifeCycle Pharma Initiates Phase II Clinical Trial of LCP-Tacro for the

Treatment of Autoimmune HepatitisFrom Hepatitis Weekly - Jan 14, 2008LifeCycle

Pharma A/S , an emerging specialty pharmaceutical company, announced that it has

initiated a Phase II clinical trial of LCP-Tacro for the treatment of autoimmune

hepatitis , also referred to as chronic active hepatitis, a disease which causes

a person's body to reject its own liver. Read Full Article Article Summary

paid advertisement

Infectious Disease Weekly is brought to you by PharmaLive.com and is a member of

the TherapeuticsDaily.com eNewsletter Series.

_________________________________________________________________

Put your friends on the big screen with Windows Vista® + Windows Live™.

http://www.microsoft.com/windows/shop/specialoffers.mspx?ocid=TXT_TAGLM_CPC_Medi\

aCtr_bigscreen_012008